Summary Effectiveness of recombinant DNA (rDNA) human interferon alpha 2 (IFN alpha 2) in advanced breast cancer was evaluated in 14 patients who had received prior endocrine and/or cytotoxic therapy. After randomization, 7 patients received IFN alpha 2 two million IUm-2day-1, s.c., 3 times a week (schedule 1) and 7 patients received 50 million IUm-2day-', i.v., for 5 consecutive days, every 3 weeks (schedule 2).
Response to human interferon alpha (IFN alpha) has been noted in advanced breast cancer in phase I trials (Gutterman et al., 1980; Sherwin et al., 1982; Horning et al., 1982) . Recombinant DNA (rDNA) human IFN alpha 2 (IFN alpha 2) is a highly purified single subtype in IFN alpha with a specific activity equal to or greater than 108IUMmg-protein. In this paper we report the results of a trial which evaluated the efficacy of IFN alpha 2 in two treatment schedules -a low dose continuous subcutaneous therapy and a high dose pulsed intravenous therapy, in advanced breast cancer. Data obtained on the pharmacokinetics, on the development of serum neutralizing factors to IFN alpha 2 and on the effect of IFN alpha 2 on the level of expression of HLA class 1 antigens and /2 microglobulin in peripheral blood lymphocytes are also presented.
Materials and methods
Female patients with histologically confirmed, evaluable, progressive advanced breast cancer refractory to standard endocrine and/or cytotoxic therapy were considered for the trial. All had a complete clinical examination with measurements and/or photographs of lesions, full blood counts, Correspondence: N. Padmanabhan Received 11 July 1984; and in WHO. criteria (WHO, 1979) . This Table shows the number of patients in whom a particular toxicity (grade >1) was noted at least once during the course of therapy.
aN Upper limit of normal, AST (SGOT) -Aspartate aminotransferase, gamma GT -gamma glutamyl transpeptidase and alk phos -alkaline phosphatase.
courses, median actual cumulative dose expressed as % projected dose of IFN alpha 2 received by patients was 70.3% with a range of 51.7 to 82.3%. The depressed leucocyte counts returned to normal in 3 to 7 days after a course of treatment) and in 2 patients an additional reason for dose reduction was either hyperglycemia or marked elevation serum AST. Treatment had to be stopped, in 2 patients on schedule 1 because of a progressive rise in the levels of serum AST and gamma glutamyl transpeptidase (gamma GT) and in 1 patient on schedule 2 because of cardiac failure. Two patients (1 in each schedule) needed transfusion of red cells for anemia and 2 patients on schedule 2 had an infective episode soon after a course of IFN alpha 2 which responded to antibiotics. Response All 14 patients were evaluable for response. The treatment duration was 9 (median) and 4-21 (range) weeks for the 7 patients on schedule 1. The disease progressed on treatment in all patients. The 7 patients on schedule 2 received 3 (median) and 2-8 (range) courses of IFN alpha 2 in 6-24 weeks. The disease progressed on treatment in 6 while in 1 patient the disease remained stable after 8 courses (in 24 weeks) of IFN alpha 2.
Subsequent course ofpatients Nine (5 and 4, schedules 1 and 2 respectively) patients have died of progressive disease after discontinuing treatment with IFN alpha 2. Two out Severity of toxicity experienced by patients during the course of treatment expressed on a weighted severity scale. Toxicity graded (0-4) according to the WHO criteria (WHO, 1979) , where no such criteria exist grading was from 0 (no symptom) to 4 (very severe toxicity). The worst grade of the side effect experienced by each patient during the course of therapy was taken and the weighted severity was calculated as follows:
Weighted severity=1 (no. of patients reporting reaction x severity)/no. of patients in the group.
AST (SGOT) -aspartate aminotransferase, gamma GT -gamma glutamyl transpeptidase and alk phos -alkaline phosphatase.
of 7 patients had partial responses to further endocrine treatment (duration of response 5 and 7 mths, 1 pt to prednisolone and 1 pt to aminoglutethimide). Four out of 12 patients had partial responses to further chemotherapy (duration of response median 4.5 mths and range 3 to 6 mths, 1 pt to adriamycin and 3 pts to mitomycin C with vinblastine).
Pharmacokinetics
Pharmacokinetic data was obtained in 6 patients on schedule 1 and in 7 patients on schedule 2 during the first week or course of therapy. In patients on schedule 1 the levels of serum IFN activity were either undetectable (1 pt) or low (5 pts). The levels rose gradually to a peak (2.5-25 IUml-1) between 2 and 8 h. At 24 h only one patient had detectable serum IFN activity (6 IU ml 1). In patients on schedule 2 the levels of serum IFN activity rose sharply with a peak (280-3904 IUml-) between 1/2 and 2 h and declined rapidly by 4 h. However, serum IFN activity was still detectable in 3 patients (62-256 IU ml-1) at 24 h.
IFN neutralizing factors
Only 1 patient out of 14 had detectable IFN neutralizing factors in her serum prior to treatment with IFN alpha 2 but none at 4 weeks (serum IFN activity in this patient during the first course of treatment ranged from 256-1826 IU ml -1 with detectable activity of 256 IU ml-I at 34 h). None of the patients had detectable IFN neutralizing factors in the serum samples obtained during and after treatment (median 10 weeks, range 4-24 weeks).
Discussion
Treatment with IFN alpha 2 was associated with significant toxicity which was dose related. Depression of bone marrow and hepatic dysfunction were the major dose limiting factors. Central nervous system toxicity was limited to somnolence and the serious toxicity noted with the use of much higher doses of IFN was not seen (Rohatiner et al., 1983; Nethersell et al., 1984) . Hyperglycemia (data on file with Schering-Plough corp.), Raynaud's phenomenon (Sangster et al., 1983) , cardiac toxicity (Oldham, 1983) , peripheral neuropathy (Gutterman et al., 1982) and other toxicities (Gutterman et al., 1980 (Gutterman et al., , 1982 Sherwin et al., 1982 Sherwin et al., , 1983 Horning et al., 1982; Borden et al., 1982; Edelstein et al., 1983) noted in this trial have been reported previously.
The lack of antitumour activity for IFN alpha 2 as noted in this trial differs from the results of studies in vitro, in animal tumour model systems and from the results of other clinical trials (Gutterman et al., 1980; Sherwin et al., 1982; Horning et al., 1982; Borden et al., 1982) . Two possible explanations can be given to account for this discrepancy. First, it is possible that a mixture of species of IFNs alpha is more active than a single species, as the phase 2 trial (Borden et al., 1982) which evaluated leukocyte derived IFN (a mixture of species of IFNs alpha) in advanced breast cancer found 5 partial responses in 23 patients (median duration of response 59 days, range 14-176 days) while the trials which evaluated a single pure species of IFN alpha found none (current trial and Sherwin et al., 1983 - evaluated rDNA human IFN alpha A which is essentially identical but differs by one amino acid from rDNA IFN alpha 2, see Pestka, 1983) .
Second, it is possible that the previous cytotoxic therapy received by patients in this trial had a role in determining the resistance of their tumours to IFN. This explanation is supported by the fact that all the patients in this trial and in the trial reported by Sherwin et al. (1983) , had received prior cytotoxic + endocrine therapy whereas patients included in the trial reported by Borden et al. (1982) , had either received no prior systemic therapy or were responders to prior endocrine therapy only and in the trial reported by Nethersell et al. (1984, evaluated rDNA human IFN alpha A) the only 2 responders (partial responses, noted at 4 wks not maintained at 12 wks) were patients who had not received prior cytotoxic therapy but were responders to prior endocrine therapy. The observations that: (a) enough serum IFN activity was present in all patients to produce some degree of toxicity, (b) serum IFN activity was detectable in 12 patients out of the 14, (c) 8 patients had changes in the level of expression of HLA class 1 antigens and/or #2 microglobulin and (d) IFN neutralizing factors were noted in only 1 patient; suggest that tumour resistance to IFN alpha 2 is the probable explanation for the lack of response noted in this trial. The observation that useful responses were obtained to further chemo and endocrine therapy suggests that IFN alpha 2 did not have an adverse influence on the outcome of subsequent treatment.
The increase in the level of expression of HLA class 1 antigens and f2 microglobulin in peripheral blood lymphocytes induced by IFN alpha 2 confirms that these changes seen in vitro (Hokland et al., 1981) , occur in vivo. It may be possible to define an optimum dose for IFN using this system as this effect seems to be dose related.
The lack of response to IFN alpha 2 in the 14 patients evaluated in this trial suggests that the rate of response to this drug when used as a single agent in advanced breast cancer in either dose schedule, is unlikely to be greater than 35% in patients who have received prior cytotoxic + endocrine therapy. If these results are considered in conjunction with the results obtained (in patients who had received prior cytotoxic + endocrine therapy) in other phase 2 trials (Sherwin et al., 1983; Nethersell et al., 1984) the response rate for IFN alpha 2 in this defined set of patients is unlikely to be greater than 20%. As some studies suggest synergism between IFN and cytotoxic drugs (Balkwill & Moodie, 1984) , the future role of this drug in advanced breast cancer will have to be defined by trials to evaluate such combinations.
